Publications
Filters: First Letter Of Keyword is N [Clear All Filters]
More insights into early brain development through statistical analyses of eigen-structural elements of diffusion tensor imaging using multivariate adaptive regression splines." Brain Struct Funct 219, no. 2 (2014): 551-69.
"Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354.
"Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354.
"Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Medical records-based postmarketing safety evaluation of rare events with uncertain status." J Biopharm Stat 23, no. 1 (2013): 201-12.
"Increase in speech recognition due to linguistic mismatch between target and masker speech: monolingual and simultaneous bilingual performance." J Speech Lang Hear Res 57, no. 3 (2014): 1089-97.
"Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008." BMC Med Res Methodol 19, no. 1 (2019): 2.
"A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94.
"A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94.
"A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94.
"CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"